Research graph
References from Economic evaluation of Qili Qiangxin capsules for the treatment of chronic heart failure. Local targets link to admitted publications; unresolved targets remain external evidence.
Prevalence of heart failure by cause in 21 regions: global burden of diseases, injuries and risk factors–2010 study
10.1016/s0735-1097(13)60786-x · 2013 · External reference
Sacubitril/valsartan: a review in chronic heart failure with reduced ejection fraction
10.1007/s40265-016-0544-9 · 2016 · External reference
10.1161/cir.0000000000001073
10.1161/cir.0000000000001073 · External reference
Investigation of prevalence and distributing feature of chronic heart failure in Chinese adult population
2003 · External reference
Prevalence and incidence of heart failure among urban patients in china: a national population-based analysis
10.1161/circheartfailure.121.008406 · 2021 · External reference
The annual global economic burden of heart failure
10.1016/j.ijcard.2013.12.028 · 2014 · External reference
Dapagliflozin in patients with heart failure and reduced ejection fraction
10.1056/nejmoa1911303 · 2019 · External reference
A multicenter, randomized, double-blind, parallel-group, placebo-controlled study of the effects of Qili Qiangxin capsules in patients with chronic heart failure
10.1016/j.jacc.2013.05.035 · 2013 · External reference
Mechanism of Qili Qiangxin capsule for heart failure based on miR133a-endoplasmic reticulum stress
10.1007/s11655-024-3654-3 · 2024 · External reference
The traditional Chinese medicine Qiliqiangxin in heart failure with reduced ejection fraction: a randomized, double-blind, placebo-controlled trial
10.1038/s41591-024-03169-2 · 2024 · External reference
Cost-effectiveness of sodium-glucose cotransporter-2 inhibitors for the treatment of heart failure with preserved ejection fraction
10.1001/jamacardio.2023.0077 · 2023 · External reference
Effectiveness and cost-effectiveness of an empowerment-based self-care education program on health outcomes among patients with heart failure: a randomized clinical trial
10.1001/jamanetworkopen.2022.5982 · 2022 · External reference
Pharmacoeconomics of ivabradine in the treatment of CHF in the context of “Quadruple Therapy”
2024 · External reference
Qiliqiangxin attenuates oxidative stress-induced mitochondrion-dependent apoptosis in cardiomyocytes via PI3K/AKT/GSK3β signaling pathway
10.1248/bpb.b19-00050 · 2019 · External reference
Qiliqiangxin alleviates Ang II-induced CMECs apoptosis by downregulating autophagy via the ErbB2-AKT-FoxO3a axis
10.1016/j.lfs.2021.119239 · 2021 · External reference
Qiliqiangxin capsule modulates calcium transients and calcium sparks in human induced pluripotent stem cell-derived cardiomyocytes
10.1155/2022/9361077 · 2022 · External reference
10.1002/ejhf.3068
10.1002/ejhf.3068 · External reference
Qiliqiangxin improves cardiac function through regulating energy metabolism via HIF-1α-dependent and independent mechanisms in heart failure rats after acute myocardial infarction
10.1155/2020/1276195 · 2020 · External reference
Qiliqiangxin improves cardiac function and attenuates cardiac remodelling in doxorubicin-induced heart failure rats
10.1080/13880209.2020.1761403 · 2020 · External reference
The efficacy and safety of a Qiliqiangxin capsule combined with sacubitril/valsartan in the treatment of chronic heart failure: a systematic review and meta-analysis
10.1155/2023/2701314 · 2023 · External reference
A contemporary appraisal of the heart failure epidemic in Olmsted County, Minnesota, 2000 to 2010
10.1001/jamainternmed.2015.0924 · 2015 · External reference
The epidemiology of heart failure, based on data for 2.1 million inhabitants in Sweden
10.1093/eurjhf/hft064 · 2013 · External reference
Analysis of long-term mortality and influencing factors in patients with chronic heart failure
2021 · External reference
